[{"address1": "2265 Upper Middle Road East", "address2": "Suite 602", "city": "Oakville", "state": "ON", "zip": "L6H 0G5", "country": "Canada", "phone": "289-910-0850", "fax": "905-481-2394", "website": "https://www.cardiolrx.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. David G. Elsley MBA", "title": "President, CEO & Director", "fiscalYear": 2023, "totalPay": 547497, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA", "title": "CFO, Corporate Secretary & Director", "fiscalYear": 2023, "totalPay": 215749, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bernard  Lim B.Sc.", "title": "Chief Operating Officer", "fiscalYear": 2023, "totalPay": 377561, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew Warwick Hamer M.D.", "age": 61, "title": "Chief Medical Officer & Head of Research & Development", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 546372, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Trevor  Burns", "title": "Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.92, "open": 1.94, "dayLow": 1.93, "dayHigh": 2.02, "regularMarketPreviousClose": 1.92, "regularMarketOpen": 1.94, "regularMarketDayLow": 1.93, "regularMarketDayHigh": 2.02, "beta": 0.672, "forwardPE": -6.6, "volume": 187810, "regularMarketVolume": 187810, "averageVolume": 504991, "averageVolume10days": 416090, "averageDailyVolume10Day": 416090, "bid": 1.96, "ask": 1.99, "bidSize": 400, "askSize": 400, "marketCap": 136818976, "fiftyTwoWeekLow": 0.661, "fiftyTwoWeekHigh": 3.12, "fiftyDayAverage": 2.2047, "twoHundredDayAverage": 1.4279, "currency": "USD", "enterpriseValue": 108210824, "floatShares": 65707783, "sharesOutstanding": 68998304, "sharesShort": 776285, "sharesShortPriorMonth": 266475, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0113, "heldPercentInsiders": 0.046269998, "heldPercentInstitutions": 0.13146, "shortRatio": 1.13, "shortPercentOfFloat": 0.0117999995, "impliedSharesOutstanding": 69100496, "bookValue": 0.294, "priceToBook": 6.734694, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -30218588, "trailingEps": -0.34, "forwardEps": -0.3, "enterpriseToEbitda": -3.581, "52WeekChange": 1.3294117, "SandP52WeekChange": 0.26253593, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CRDL", "underlyingSymbol": "CRDL", "shortName": "Cardiol Therapeutics Inc.", "longName": "Cardiol Therapeutics Inc.", "firstTradeDateEpochUtc": 1547562600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ee9d962b-eed4-3063-8df9-c815990fe5d8", "messageBoardId": "finmb_424954803", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.98, "targetHighPrice": 9.98, "targetLowPrice": 7.98, "targetMeanPrice": 8.98, "targetMedianPrice": 8.98, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 28572976, "totalCashPerShare": 0.414, "ebitda": -30222164, "totalDebt": 167136, "quickRatio": 2.646, "currentRatio": 2.807, "debtToEquity": 0.833, "returnOnAssets": -0.45347, "returnOnEquity": -0.92109, "freeCashflow": -9735083, "operatingCashflow": -22156452, "financialCurrency": "CAD", "trailingPegRatio": null, "__fetch_time": "2024-07-08"}]